{"ok":true,"nota":{"id":"ca5da46af78acded","slug":"una-ia-sobre-biopsias-predice-quien-no-necesita-quimioterapia-en-cance-ca5da4","titulo":"Una IA sobre biopsias predice quién no necesita quimioterapia en cáncer de mama","resumen":"Se validó de forma ciega un modelo de IA que analiza imágenes de tejido y datos clínicos en 677 mujeres con cáncer de mama hormonosensible y ganglios comprometidos, usando datos de un ensayo clínico de los años noventa. Compara un puntaje solo de imagen con uno multimodal.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Thompson, A. M., Meisner, A., Albain, K. S., Tang, C., Biswas, D., Park, J., Zeng, K., Cappadona, J., Liu, C., McClean, ","url":"https://www.medrxiv.org/content/10.64898/2026.10.21.26366092v1?rss=1","imagen":"/hoy/portada/ca5da46af78acded","tema":"salud","subtemas":["cáncer de mama","inteligencia artificial en medicina","quimioterapia","biomarcadores","medicina de precisión"],"entidades":["SWOG-8814","Ataraxis Breast CTX"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-23T00:00:00.000Z","indexTs":"2026-10-23T18:12:31.737Z","hash":"8d37467fa085fc8dd412073576041e8dacc3562b504a536ed44f51212a17c4ce","tsa":{"time":"Oct 23 18:13:30 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Hoy muchas pacientes reciben quimioterapia sin que quede claro si la necesitan, y los test genómicos que lo aclaran son caros y consumen tejido. Una herramienta que sale de una biopsia ya existente podría ahorrarle a una mujer un tratamiento pesado y a un sistema de salud un gasto grande. Pero el estudio usa datos de un ensayo viejo y de menos de la mitad de los pacientes inscriptos. Antes de cambiar una decisión clínica hace falta ver cómo se comporta en pacientes actuales.","quienFirma":"Ataraxis AI y grupo de investigación con datos del ensayo SWOG-8814 (EE.UU.)","confianza":"preprint","consulta":null},"sello":{"hash":"8d37467fa085fc8dd412073576041e8dacc3562b504a536ed44f51212a17c4ce","sello":"bb7fb3f82d25fa8f4c8fcb7d00004bf606ed5e162e9e2ef57fad939db285b7d6","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6578272,"aleatorio":"e504aca3fcd7243fddbec8b88f1c51dc96cb1f827ccda23c013f3b302f3c69ab","tiempo":"2026-10-23T18:13:00.000Z"},"nist":{"cadena":2,"pulso":1996329,"salida":"880EE1B503674E57D0E81D7CEC0FFDBB3A3BB5CD5A62E05BB575BBCB9E2DB29F611799CDCF1B120D62E8DF3A39AE0D1B9935A0A198FC708C5974107E51CFF0C4","tiempo":"2026-10-23T18:12:00.000Z"},"noAntes":"2026-10-23T18:13:00.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 23 18:13:30 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"AI-based prognosis and chemotherapy benefit in node-positive, HR+ breast cancer: a blinded external validation on SWOG-8814 trial","descripcion":"Background The benefit from adjuvant chemotherapy varies among patients with postmenopausal, node-positive, hormone receptor-positive breast cancer. Genomic assays identify patients likely to benefit from chemotherapy but are expensive and tissue consuming. AI-enabled biomarkers may provide scalable alternatives. We performed a blinded external evaluation of Ataraxis Breast CTX, a causal multi-modal AI model that integrates H&E images with clinical variables, in the phase III SWOG-8814 trial. Methods The analytic cohort comprised 677 patients (46% of the 1477 enrolled) with digitized H&E slides. Two CTX scores were evaluated: a histology-only score and a multi-modal score integrating patholo","pubDate":"2026-10-23","url":"https://www.medrxiv.org/content/10.64898/2026.10.21.26366092v1?rss=1"},"indexado":"2026-10-23T18:12:31.737Z"}}